After the recent discovery of various mutations of theCALRgene,,10% of adult patients with essential thrombocythemia (ET) orprimary myelofibrosis carry no identified molecular markers.1,2More rarely, ET may occur also in children and adolescents.3Weevaluated, by Sanger sequencing, the mutation status of exon 9 oftheCALRgene in 34 ET patients younger than 20 years of age atdiagnosis (median age, 15 years; range, 1-19 years). The study wasapproved by the Institutional Ethic Committee
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and the Calreticulin (CALR...
CALR (calreticulin) trails JAK2 as the second most mutated gene in essential thrombocythemia (ET). M...
Essential thrombocythemia (ET) is a rare myeloproliferative disorder occurring predominantly in the ...
Essential thrombocythemia (ET) is rare in children, and little or no information is available about ...
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescenc
Essential thrombocythemia (ET) is rare in children, and little or no information is available about ...
Sporadic essential thrombocythaemia (ET) is rare in paediatrics, and the diagnostic and clinical app...
This paper reviews the features of pediatric essential thrombocythemia (ET). ET is a rare disease in...
This paper reviews the features of pediatric essential thrombocythemia (ET). ET is a rare disease in...
We investigated the influence of molecular status on disease characteristics and clinical outcome in...
The recent discovery of various mutations of the CALR gene that are mutually exclusive with JAK2 and...
Somatic mutations in the calreticulin (CALR) gene were recently discovered in patients with sporadic...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mu...
Background. Essential thrombocythemia (ET) and primary myelofibrosis (MF) are myeloproliferative ne...
Abstract Essential thrombocythemia (ET) is extremely rare in the pediatric population. In most pati...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and the Calreticulin (CALR...
CALR (calreticulin) trails JAK2 as the second most mutated gene in essential thrombocythemia (ET). M...
Essential thrombocythemia (ET) is a rare myeloproliferative disorder occurring predominantly in the ...
Essential thrombocythemia (ET) is rare in children, and little or no information is available about ...
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescenc
Essential thrombocythemia (ET) is rare in children, and little or no information is available about ...
Sporadic essential thrombocythaemia (ET) is rare in paediatrics, and the diagnostic and clinical app...
This paper reviews the features of pediatric essential thrombocythemia (ET). ET is a rare disease in...
This paper reviews the features of pediatric essential thrombocythemia (ET). ET is a rare disease in...
We investigated the influence of molecular status on disease characteristics and clinical outcome in...
The recent discovery of various mutations of the CALR gene that are mutually exclusive with JAK2 and...
Somatic mutations in the calreticulin (CALR) gene were recently discovered in patients with sporadic...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mu...
Background. Essential thrombocythemia (ET) and primary myelofibrosis (MF) are myeloproliferative ne...
Abstract Essential thrombocythemia (ET) is extremely rare in the pediatric population. In most pati...
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and the Calreticulin (CALR...
CALR (calreticulin) trails JAK2 as the second most mutated gene in essential thrombocythemia (ET). M...
Essential thrombocythemia (ET) is a rare myeloproliferative disorder occurring predominantly in the ...